| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -40,316 | -27,279 |
| Purchases of property and equipment | 37 | 31 |
| Net cash used in investing activities | -37 | -31 |
| Payment of issuance costs associated with the concurrent financing-Private Placement | 37 | 37 |
| Payment of reverse recapitalization transaction costs | 40 | 40 |
| Net cash (used in) provided by financing activities | -77 | -77 |
| Net decrease in cash and cash equivalents | -40,430 | -27,387 |
| Cash and cash equivalents at beginning of period | 110,761 | - |
| Cash and cash equivalents at end of period | 70,331 | - |
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)